BR9915027A - Derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego - Google Patents

Derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego

Info

Publication number
BR9915027A
BR9915027A BR9915027-1A BR9915027A BR9915027A BR 9915027 A BR9915027 A BR 9915027A BR 9915027 A BR9915027 A BR 9915027A BR 9915027 A BR9915027 A BR 9915027A
Authority
BR
Brazil
Prior art keywords
pyridin
derivatives
diaryl
propanol
ylamino
Prior art date
Application number
BR9915027-1A
Other languages
English (en)
Other versions
BR9915027B1 (pt
Inventor
Reinhard Kirsch
Alfons Enhsen
Heiner Glombik
Werner Kramer
Eugen Falk
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9915027A publication Critical patent/BR9915027A/pt
Publication of BR9915027B1 publication Critical patent/BR9915027B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE 1,3-DIARIL-2-PIRIDIN-2-IL-3-(3-PIRIDIN-2-ILAMINO)-PROPANOL SUBSTITUìDOS, PROCESSOS PARA A SUA PREPARAçãO, MEDICAMENTOS CONTENDO ESTES COMPOSTOS E SEU EMPREGO"<D>. A invenção refere-se a derivados de 1,3-diaril-2-piridin-2-il-3-(piridin-2-ilamino)-propanol substituídos e seus sais farmaceuticamente compatíveis e derivados fisiologicamente funcionais. São descritos derivados de 1,3-diaril-2-piridin-2-il-3-(piridin-2-ilamino)-propanol substituídos da fórmula I copiar fórmula página 79, na qual os radicais têm os significados indicados, bem como seus sais fisiologicamente compatíveis e processos para sua preparação. Os compostos prestam-se, por exemplo, como hipolipidêmicos.
BRPI9915027-1A 1998-10-02 1999-09-18 derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos. BR9915027B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845406A DE19845406C2 (de) 1998-10-02 1998-10-02 Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP1999/006933 WO2000020393A1 (de) 1998-10-02 1999-09-18 Substituierte 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (2)

Publication Number Publication Date
BR9915027A true BR9915027A (pt) 2001-07-17
BR9915027B1 BR9915027B1 (pt) 2010-09-08

Family

ID=7883187

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915027-1A BR9915027B1 (pt) 1998-10-02 1999-09-18 derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos.

Country Status (23)

Country Link
US (1) US6596728B1 (pt)
EP (1) EP1117642B1 (pt)
JP (1) JP4544746B2 (pt)
KR (1) KR100609255B1 (pt)
CN (1) CN1173951C (pt)
AR (1) AR021845A1 (pt)
AT (1) ATE267809T1 (pt)
AU (1) AU757689B2 (pt)
BR (1) BR9915027B1 (pt)
CA (1) CA2345985C (pt)
CZ (1) CZ299569B6 (pt)
DE (2) DE19845406C2 (pt)
DK (1) DK1117642T3 (pt)
ES (1) ES2219066T3 (pt)
HK (1) HK1051533A1 (pt)
HU (1) HU226688B1 (pt)
ID (1) ID29249A (pt)
PL (1) PL205034B1 (pt)
PT (1) PT1117642E (pt)
RU (1) RU2224748C2 (pt)
TR (1) TR200100896T2 (pt)
WO (1) WO2000020393A1 (pt)
ZA (1) ZA200102587B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516289A (ja) 2000-12-21 2004-06-03 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジフェニルアゼチジノン誘導体、その調製方法、その化合物を含む薬剤およびその使用
JP2005505538A (ja) * 2001-08-22 2005-02-24 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アリール置換プロパノールアミン誘導体と他の活性成分との組み合わせ物およびその使用
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
DE10219987A1 (de) * 2002-05-03 2004-04-08 Aventis Pharma Deutschland Gmbh Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
EP1678168B1 (en) * 2003-10-24 2012-07-11 Exelixis, Inc. P70s6 kinase modulators and method of use
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
AU2020221834A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000816A1 (en) * 1977-08-06 1979-02-21 Beecham Group Plc Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
ATE268758T1 (de) * 1997-04-04 2004-06-15 Aventis Pharma Gmbh Hypolipidämische propanolaminderivate
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung

Also Published As

Publication number Publication date
HUP0103533A3 (en) 2003-01-28
CN1173951C (zh) 2004-11-03
DE19845406C2 (de) 2001-10-18
AR021845A1 (es) 2002-08-07
KR20010075496A (ko) 2001-08-09
US6596728B1 (en) 2003-07-22
AU757689B2 (en) 2003-03-06
CZ299569B6 (cs) 2008-09-03
TR200100896T2 (tr) 2001-09-21
ATE267809T1 (de) 2004-06-15
WO2000020393A1 (de) 2000-04-13
ZA200102587B (en) 2001-11-05
HU226688B1 (hu) 2009-06-29
CN1391558A (zh) 2003-01-15
PT1117642E (pt) 2004-09-30
JP2002526530A (ja) 2002-08-20
CZ20011152A3 (cs) 2001-07-11
DK1117642T3 (da) 2004-08-09
PL347096A1 (en) 2002-03-25
ID29249A (id) 2001-08-16
JP4544746B2 (ja) 2010-09-15
AU6192699A (en) 2000-04-26
BR9915027B1 (pt) 2010-09-08
DE19845406A1 (de) 2000-04-13
EP1117642B1 (de) 2004-05-26
CA2345985A1 (en) 2000-04-13
HK1051533A1 (en) 2003-08-08
RU2224748C2 (ru) 2004-02-27
HUP0103533A2 (hu) 2002-02-28
PL205034B1 (pl) 2010-03-31
KR100609255B1 (ko) 2006-08-04
CA2345985C (en) 2010-06-29
ES2219066T3 (es) 2004-11-16
DE59909606D1 (de) 2004-07-01
EP1117642A1 (de) 2001-07-25

Similar Documents

Publication Publication Date Title
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR9914266A (pt) Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR9912188A (pt) Derivados de 1,1-dióxido de benzo (b) tiepina, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0116325A (pt) 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
BR0116322A (pt) Derivados de difenilazetidinona, processo para sua preparação, medicamentos contendo esses compostos e seu emprego
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BR0116482A (pt) Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego.
BR9814416A (pt) &#34;estratrienos substituìdos por 11beta-halogeno-7alfa, processos para a preparação de preparados farmacêuticos, que contêm estes estratrienos substituìdos por 11-beta-7alfa, bem como seu emprego para a preparação de medicamentos&#34;
BR9915027A (pt) Derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0108605A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d]tiazol, que na posição 8a são substituìdos; processos para a sua preparação e seu emprego como medicamentos, por exemplo, como anoréxicos
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0212158A (pt) Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BR9912562A (pt) Derivados de pirazol substituìdos condensados com anéis heterocìclicos com seis elementos
BRPI9917007B8 (pt) azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso
BR0013727A (pt) Derivados de sulfonilcarboxamida, processo para sua preparação e seu uso como medicamento
BR0211989A (pt) Compostos bicìclicos aromáticos substituìdos por aminoalquila, métodos para a sua preparação e seu uso como produtos farmacêuticos
BR9912240A (pt) Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos
BRPI0407507A (pt) derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona, processos para sua preparação de sua aplicação como medicamento
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0311896A (pt) Difenilazetidinonas substituìdas com grupos ácidos, processo para sua preparação, medicamentos contendo estes compostos e seu uso

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: REFERENTE A RPI 1865 DE 03/10/2006 COD. (25.1), POR TER SIDO INDEVIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 401/12, C07D 401/14, C07D 409/14, C07D 405/14, C07D 417/14, C07D 471/01, C07D 473/08, C07D 473/34, C07D 413/14, A61K 31/44, A61K 31/513, A61K 31/437, A61K 31/52, A61K 31/522, A61P 3/06, A61P 9/10

Ipc: C07D 401/12 (2009.01), C07D 401/14 (2009.01), C07D

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.